LPPLPP SA
20860.00PLN+0.77%Mkt Cap: 9.74B $P/E: 23.50

LPP SA designs, manufactures, and distributes apparel for women, men, and children. It offers apparel, accessories, footwear, and supplementary items under the Reserved, Cropp, House, Mohito, and Sinsay brand names. The …

HeadlineSourceTime
This week
PParkiet
Stooq
Older
Stooq
PParkiet
RRzeczpospolita
Stooq
BBusiness Insider Polska
wnp.pl
SStrefa Inwestorów
BBIZNES24
Investing.com Polska: Kursy walut, kryptowalut, notowania akcji
SStrefa Inwestorów
Bankier.pl
RRzeczpospolita
PParkiet
NNext Gazeta.pl
rmf24.pl
Stooq
SStrefa Inwestorów
SStrefa Inwestorów
SStrefa Inwestorów
SStrefa Inwestorów
SStrefa Inwestorów
Trojmiasto.pl
BBIZNES24
Stooq
GuruFocus.com
BBIZNES24
Inwestycje.pl
LPP SA (WAR:LPP) Full Year 2025 Earnings Call Highlights: Record Growth and Strategic ...

LPP SA (WAR:LPP) reports a robust 19% revenue increase, significant store expansion, and strategic investments in logistics and automation, setting the stage for future growth.

GuruFocus.com
LPP shares surge as Q3 profit jumps on strong sales growth

Investing.com - Polish fashion retailer LPP SA (WA:LPPP) on Thursday reported a 39% increase in third-quarter net profit to PLN 800 million as revenue climbed 22% YoY to over PLN 6 billion, driven by strong performance across both online and physical store channels.

Investing.com
Heineken’s Strongbow adds NaviLens levels to packaging

The cider brand has added a high-contrast NaviLens QR code to its cans.

Packaging Gateway
3 firms to lay off hundreds of North Jersey-based employees

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

The Bergen Record
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters
Novartis to acquire Tourmaline Bio for $1.4 billion

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Reuters